Emergent Biosolutions(EBS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EBS Emergent Biosolutions

交易中 07-01 15:44:42 EDT

8.42

+0.03

+0.30%

最高8.63	最低8.30	成交量33.88万
今开8.31	昨收8.39	日振幅3.93%
总市值4.36亿	流通市值4.31亿	总股本5,177万
成交额285.49万	换手率0.66%	流通股本5,126万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EBS","market":"US","secType":"STK","nameCN":"Emergent Biosolutions","latestPrice":8.415,"timestamp":1782935079160,"preClose":8.39,"halted":0,"volume":338777,"delay":0,"changeRate":0.0029797377830749197,"floatShares":51257100,"shares":51770857,"eps":-0.212879,"marketStatus":"交易中","change":0.025,"latestTime":"07-01 15:44:42 EDT","open":8.31,"high":8.63,"low":8.3,"amount":2854928.660874,"amplitude":0.039333,"askPrice":8.42,"askSize":270,"bidPrice":8.41,"bidSize":148,"shortable":3,"etf":0,"ttmEps":-0.212879,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1782936000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1254456000000,"exchange":"NYSE","adjPreClose":8.39,"preHourTrading":{"tag":"盘前","latestPrice":8.38,"preClose":8.39,"latestTime":"08:39 EDT","volume":1028,"amount":8648.948472,"timestamp":1782909592300,"change":-0.01,"changeRate":-0.001192,"amplitude":0.06317},"postHourTrading":{"tag":"盘后","latestPrice":8.38,"preClose":8.38,"latestTime":"17:12 EDT","volume":7689,"amount":64433.87,"timestamp":1782853971211,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.325742,"impliedVol":0.7681,"impliedVolPercentile":0.6454},"requestUrl":"/m/hq/s/EBS","defaultTab":"news","newsList":[{"id":"1169864105","title":"Emergent BioSolutions首季营收达1.561亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169864105","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169864105?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:47","pubTimestamp":1777582055,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions公布第一季度调整后净利润为1190万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191409964","title":"Emergent BioSolutions获新加坡卫生科学局批准扩大Acam2000®适应症至猴痘","url":"https://stock-news.laohu8.com/highlight/detail?id=1191409964","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191409964?lang=zh_cn&edition=full","pubTime":"2026-04-30 19:56","pubTimestamp":1777550192,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions宣布，新加坡卫生科学局已批准扩大其Acam2000®（天花和猴痘（痘苗）活疫苗）的适应症范围，将猴痘预防纳入其中。此次批准标志着该疫苗在亚太地区传染病防控领域取得重要进展。\nAcam2000®作为新一代天花疫苗，此次适应症扩展将强化全球应对猴痘疫情的疫苗储备体系。该公司表示，这一监管批准将有助于提升亚太地区对正痘病毒属疾病的防控能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170248288","title":"Emergent BioSolutions与SAB Biotherapeutics达成协议 将提供端到端开发与制造服务","url":"https://stock-news.laohu8.com/highlight/detail?id=1170248288","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170248288?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:37","pubTimestamp":1777462666,"startTime":"0","endTime":"0","summary":"根据协议条款，Emergent BioSolutions将为SAB Biotherapeutics提供涵盖从研发到生产的全流程服务。此次合作将充分发挥Emergent在生物制药领域的技术专长和制造能力。\n两家公司此次达成的战略合作，标志着在生物制药外包服务领域的深度整合。通过这项端到端服务协议，SAB Biotherapeutics有望加速其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4583","SABS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184841750","title":"Emergent BioSolutions与SAB Biotherapeutics达成长期战略生产协议 共同推进1型糖尿病候选药物SAB-142","url":"https://stock-news.laohu8.com/highlight/detail?id=1184841750","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184841750?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:35","pubTimestamp":1777462515,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions与SAB Biotherapeutics, Inc.正式签署长期战略生产合作协议，双方将携手推进针对1型糖尿病的候选药物SAB-142的研发进程。这项合作标志着两家生物技术企业在糖尿病治疗领域迈出重要一步，通过整合双方在生物制药生产与技术研发方面的专业优势，为SAB-142的临床开发与未来商业化生产提供坚实保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SABS","BK4583","BK4139","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173150485","title":"Emergent BioSolutions坎顿工厂将生产原料药并获独家分销权","url":"https://stock-news.laohu8.com/highlight/detail?id=1173150485","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173150485?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:05","pubTimestamp":1777377936,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions公司宣布，其坎顿生产基地将启动原料药生产业务，并同步获得相关产品的独家分销权限。这一战略布局将强化该公司在生物制药领域的供应链控制力与市场影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122224457","title":"Emergent BioSolutions与不列颠哥伦比亚省达成合作 为扩大版家庭纳洛酮计划供应Narcan®鼻喷雾剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1122224457","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122224457?lang=zh_cn&edition=full","pubTime":"2026-04-10 04:26","pubTimestamp":1775766371,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions宣布与加拿大不列颠哥伦比亚省建立合作伙伴关系，将为该省扩大家庭纳洛酮计划提供Narcan®鼻喷雾剂。此次合作旨在通过提高纳洛酮的可及性，支持当地应对阿片类药物过量危机的公共卫生行动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128008188","title":"应急生物解决方案公司宣布任命小约翰·D·福勒为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1128008188","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128008188?lang=zh_cn&edition=full","pubTime":"2026-03-03 21:05","pubTimestamp":1772543129,"startTime":"0","endTime":"0","summary":"马里兰州盖瑟斯堡，2026年3月3日——应急生物解决方案公司今日宣布，任命小约翰·D·福勒为其董事会成员，该任命自2026年3月1日起生效。福勒先生在医疗健康和金融服务领域拥有超过三十年的领导经验。他将任职于审计与财务委员会。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EBS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177146443","title":"Emergent BioSolutions获FDA批准Narcan鼻喷雾多包装补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1177146443","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177146443?lang=zh_cn&edition=full","pubTime":"2026-02-13 07:00","pubTimestamp":1770937212,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准Emergent BioSolutions公司提交的Narcan®鼻喷雾多包装补充新药申请。这一审批标志着该产品在包装形式上获得重要扩展，为用药便利性和可及性带来提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605742942","title":"Emergent Biosolutions Inc.盘中异动 急速拉升5.04%报12.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605742942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605742942?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:13","pubTimestamp":1769094782,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时13分，Emergent Biosolutions Inc.股票出现异动，股价大幅上涨5.04%。截至发稿，该股报12.08美元/股，成交量9.7464万股，换手率0.19%，振幅4.43%。Emergent Biosolutions Inc.股票所在的制药行业中，整体涨幅为0.72%。其相关个股中，脑再生科技、Shuttle Pharmaceuticals Holdings, Inc.、Scilex Holding Company涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Akanda Corp.、Inmed Pharmaceuticals Inc.较为活跃，换手率分别为27.62%、6.90%、1.72%，振幅较大的相关个股有脑再生科技、Shuttle Pharmaceuticals Holdings, Inc.、Apimeds Pharmaceuticals Us, Inc.，振幅分别为46.51%、26.96%、13.09%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231303a44a7841&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231303a44a7841&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EBS","BK4139","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163083735","title":"Emergent BioSolutions获FDA批准Narcan®鼻喷雾剂新包装补充申请 便携式包装盒提升纳洛酮日常急救可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1163083735","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163083735?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:04","pubTimestamp":1768395877,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Emergent BioSolutions提交的Narcan®鼻喷雾剂补充新药申请。该批准允许这款救命药物纳洛酮采用新型便携式包装盒，显著提升其在日常应急场景中的可及性。\n新型携带式包装设计旨在简化取用流程，使非专业人员在紧急情况下能快速实施用药。作为阿片类药物过量逆转的关键救治手段，纳洛酮的可及性提升将有效强化社区急救网络建设。\n此次监管突破标志着 Emergent BioSolutions 在扩大公共健康安全防护范围方面取得重要进展。通过优化药品包装的便携性与识别度，企业进一步践行其提升紧急医疗产品可及性的核心使命。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603680932","title":"Emergent Biosolutions Inc.盘中异动 大幅下跌5.38%报12.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603680932?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:33","pubTimestamp":1768228386,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时33分，Emergent Biosolutions Inc.股票出现波动，股价急速下挫5.38%。截至发稿，该股报12.26美元/股，成交量23.3056万股，换手率0.44%，振幅9.94%。Emergent Biosolutions Inc.股票所在的制药行业中，整体涨幅为0.17%。其相关个股中，Bioage Labs, Inc.、Akanda Corp.、Ani Pharmaceuticals, Inc.涨幅较大，Akanda Corp.、苏轩堂、Painreform Ltd.较为活跃，换手率分别为218.29%、38.19%、3.04%，振幅较大的相关个股有Emergent Biosolutions Inc.、Akanda Corp.、苏轩堂，振幅分别为9.94%、6.13%、5.96%。Emergent Biosolutions Inc.公司简介：Emergent BioSolutions Inc 为政府和医疗保健提供商提供公共卫生产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223307a7120561&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223307a7120561&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","BK4139","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133582145","title":"Emergent BioSolutions宣布偿还1亿美元定期贷款本金，迈向多年转型战略的重要里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1133582145","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133582145?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:32","pubTimestamp":1768221133,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions于近日宣布完成对定期贷款本金1亿美元的偿付计划，这一举措标志着该公司在其制定的多年转型道路上取得了实质性突破。此次债务结构的优化不仅有效减轻了企业财务负担，更展现出管理层对战略重组的坚定执行力。\n通过主动削减债务规模，企业得以释放更多现金流用于核心业务聚焦与技术升级，为长期可持续发展奠定坚实基础。这一财务决策与公司此前公布的转型蓝图高度契合，彰显出其通过资本结构优化驱动业务蜕变的清晰路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4139","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173193947","title":"Emergent BioSolutions获美国战争部2150万美元订单，将于2026年供应炭疽疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1173193947","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173193947?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:32","pubTimestamp":1767907940,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions Inc (EBS) 宣布获得美国战争部一份价值2150万美元的订单，为其供应炭疽疫苗Biothrax，预计交付时间为2026年。该订单进一步巩固了公司在生物防御领域的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4139","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182283796","title":"Emergent BioSolutions与Panther达成协议 支持非洲CDC主导的Mpox研究在非洲持续开展","url":"https://stock-news.laohu8.com/highlight/detail?id=1182283796","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182283796?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:05","pubTimestamp":1767877534,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions与Panther公司共同宣布，双方已签署一项合作协议，旨在为非洲疾病控制与预防中心（Africa CDC）主导的Mpox病毒研究项目在非洲大陆的持续推进提供支持。该合作将强化区域公共卫生应对能力，助力传染病防控研究体系的完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518822412","title":"Emergent Biosolutions Inc.盘中异动 早盘快速下跌5.20%报5.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518822412","media":"市场透视","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518822412?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:35","pubTimestamp":1741613729,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时35分，Emergent Biosolutions Inc.股票出现波动，股价大幅跳水5.20%。截至发稿，该股报5.47美元/股，成交量5.3544万股，换手率0.10%，振幅1.56%。Emergent Biosolutions Inc.股票所在的制药行业中，整体跌幅为0.64%。其相关个股中，Sonoma Pharmaceuticals, Inc.、Alpha Teknova, Inc.、Flora Growth Corp.涨幅较大，Sonoma Pharmaceuticals, Inc.、Petros Pharmaceuticals, Inc.、苏轩堂较为活跃，换手率分别为52.14%、8.77%、2.85%，振幅较大的相关个股有Shuttle Pharmaceuticals Holdings, Inc.、惠普森医药、Alpha Teknova, Inc.，振幅分别为13.84%、12.67%、12.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213529a26a2645&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213529a26a2645&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EBS","BK4139","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677553","title":"Emergent Biosolutions Inc.股价重挫15.96% 市值跌4963.83万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677553","media":"市场透视","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677553?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:32","pubTimestamp":1741098779,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时32分，Emergent Biosolutions Inc.股票出现异动，股价快速下跌15.96%。截至发稿，该股报5.74美元/股，成交量35.3898万股，换手率0.65%，振幅4.39%。Emergent Biosolutions Inc.股票所在的制药行业中，整体跌幅为0.02%。Emergent Biosolutions Inc.公司简介：Emergent BioSolutions Inc 向政府和医疗保健提供者提供公共卫生产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223259abe7f004&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223259abe7f004&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516966912","title":"Emergent BioSolutions(EBS.US)：2024年Q4财报实现营收1.947亿美元，前值为2.766亿美元，预期值为2.547亿美元；每股收益为0.05美元，前值为-0.77美元，预期值为-0.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516966912","media":"金融界","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516966912?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:32","pubTimestamp":1741037576,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions(EBS.US)：2024年Q4财报实现营收1.947亿美元，前值为2.766亿美元，预期值为2.547亿美元；每股收益为0.05美元，前值为-0.77美元，预期值为-0.50美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04053248499197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101283831","title":"Emergent BioSolutions第四季度调整后每股收益$0.05，超出预期$(0.49)，销售额$194.70M不及预期$254.67M","url":"https://stock-news.laohu8.com/highlight/detail?id=1101283831","media":"财报速递","labels":["merge","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101283831?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:31","pubTimestamp":1741037470,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions报告的季度每股收益为$0.05，比分析师预期的$高出110.2%。公司报告的季度销售额为$194.70M，不及分析师预期的$254.67M，低23.55%。这比去年同期的销售额$276.60M减少了29.61%。以上内容来自Benzinga Earnings专栏，原文如下：Emergent BioSolutions  reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $ by 110.2 percent. This is a 106.49 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $194.70 million which missed the analyst consensus estimate of $254.67 mi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Emergent BioSolutions第四季度调整后每股收益$0.05，超出预期$(0.49)，销售额$194.70M不及预期$254.67M","news_tag":"merge,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516765030","title":"Emergent Biosolutions Inc.盘中异动 下午盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516765030","media":"市场透视","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516765030?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:28","pubTimestamp":1741030121,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时28分，Emergent Biosolutions Inc.股票出现异动，股价快速下跌5.01%。截至发稿，该股报7.11美元/股，成交量86.0413万股，换手率1.59%，振幅6.63%。Emergent Biosolutions Inc.股票所在的制药行业中，整体涨幅为1.03%。Emergent Biosolutions Inc.公司简介：Emergent BioSolutions Inc 向政府和医疗保健提供者提供公共卫生产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304032841a25d920f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304032841a25d920f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516237176","title":"Emergent Biosolutions Inc.盘中异动 临近午盘股价大涨5.10%报7.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516237176","media":"市场透视","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516237176?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:48","pubTimestamp":1740761281,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时48分，Emergent Biosolutions Inc.股票出现异动，股价快速拉升5.10%。截至发稿，该股报7.42美元/股，成交量25.5917万股，换手率0.47%，振幅6.37%。Emergent Biosolutions Inc.股票所在的制药行业中，整体跌幅为0.10%。Emergent Biosolutions Inc.公司简介：Emergent BioSolutions Inc 向政府和医疗保健提供者提供公共卫生产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010048019634390c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010048019634390c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","EBS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emergentbiosolutions.com","stockEarnings":[{"period":"1week","weight":0.0462},{"period":"1month","weight":-0.0811},{"period":"3month","weight":0},{"period":"6month","weight":-0.322},{"period":"1year","weight":0.3135},{"period":"ytd","weight":-0.322}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":-0.0128},{"period":"3month","weight":0.1397},{"period":"6month","weight":0.0951},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emergent Biosolutions Inc.于1998年5月在美国密歇根州成立，随后在 2004年6月改为特拉华公司。公司拥有两个经营部门：生物防卫和生物科学。该公司是一家全球性生命科学公司，专注于提供创新的准备和响应解决方案，以应对意外、故意和自然发生的公共健康威胁。","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.042008},{"month":2,"riseRate":0.4,"avgChangeRate":-0.01419},{"month":3,"riseRate":0.45,"avgChangeRate":-0.032712},{"month":4,"riseRate":0.45,"avgChangeRate":-0.034251},{"month":5,"riseRate":0.6,"avgChangeRate":0.111052},{"month":6,"riseRate":0.6,"avgChangeRate":0.007243},{"month":7,"riseRate":0.578947,"avgChangeRate":0.106316},{"month":8,"riseRate":0.473684,"avgChangeRate":-0.017792},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.034511},{"month":10,"riseRate":0.578947,"avgChangeRate":0.029583},{"month":11,"riseRate":0.578947,"avgChangeRate":-0.002144},{"month":12,"riseRate":0.6,"avgChangeRate":0.044099}],"exchange":"NYSE","name":"Emergent Biosolutions","nameEN":"Emergent BioSolutions"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emergent Biosolutions(EBS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emergent Biosolutions(EBS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emergent Biosolutions,EBS,Emergent Biosolutions股票,Emergent Biosolutions股票老虎,Emergent Biosolutions股票老虎国际,Emergent Biosolutions行情,Emergent Biosolutions股票行情,Emergent Biosolutions股价,Emergent Biosolutions股市,Emergent Biosolutions股票价格,Emergent Biosolutions股票交易,Emergent Biosolutions股票购买,Emergent Biosolutions股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emergent Biosolutions(EBS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emergent Biosolutions(EBS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}